Physician profile
Elia Fanous
NPI 1659308047
$1,826.88
in general payments reported to CMS, 2019-2025
24 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $76.28 · 2021: $61.90 · 2022: $682 · 2023: $384 · 2024: $326 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.14 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $417.59 | 2020-2023 | |
| Shield Therapeutics INC | $257.62 | 2023-2025 | Accrufer |
| Astellas Pharma US INC | $219.85 | 2023-2024 | Veozah, Myrbetriq |
| Gynesonics, INC. | $160.59 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exeltis, USA INC. | $132.73 | 2022-2025 | Slynd |
| Lupin INC. | $128.16 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $73.05 | 2023-2025 | |
| Biogen, INC. | $57.88 | 2024-2025 | Zurzuvae |
| Organon LLC | $53.42 | 2025 | Nexplanon |
| Hologic Sales and Service, LLC | $39.55 | 2022 | |
| Myovant Sciences INC. | $37.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.34 | 2022 | |
| Merck Sharp & Dohme LLC | $28.42 | 2024 | Gardasil, Gardasil 9 |
| Vertical Pharmaceuticals, LLC | $23.98 | 2019 | |
| Abbott Laboratories | $23.82 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $22.14 | 2022 | |
| Pfizer INC. | $19.74 | 2022 | |
| Sumitomo Pharma America, INC. | $18.02 | 2023 | Myfembree |
| Myriad Women'S Health, INC. | $15.55 | 2023 | Myrisk |
| Allergan, INC. | $15.32 | 2020 | |
| Agile Therapeutics, INC. | $15.13 | 2023 | Twirla |
| Coopersurgical, INC. | $13.78 | 2024 | Summit Doppler |
| Minerva Surgical, INC | $11.99 | 2022 | |
| Evofem Biosciences, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elia Fanous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.